Becton, Dickinson and Company (BDX) Stock Forecast & Price Target

Becton, Dickinson and Company
Bull Case

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

• Becton, Dickinson and Company recently announced a $19 billion investment in U.S. manufacturing, including $3 billion specifically for domestic medical consumables capacity, which aims to boost supply-chain resilience and potentially benefit from tariff relief.
• The company's Revello stent demonstrated strong nine-month results in the AGILITY trial for peripheral artery disease patients, showing high vessel patency and low failure rates, which strengthens its position in the peripheral vascular market.
• With a current stock price of $193.82, the stock is trading near its 52-week high of $194.34, reflecting strong recent momentum and a significant increase from its 52-week low of $127.59.
• Becton, Dickinson and Company offers a dividend yield of 2.22%, providing a steady income stream for investors, with a recent quarterly dividend of $1.05 per share paid in September 2026.
• The company has a low beta of 0.21, indicating that its stock price is less volatile than the overall market, which may appeal to investors seeking stability in their portfolio.